Jack Seitz and Lara Rosenbaum Join CONNEQT’s Executive Team

Jack Seitz joins the CONNEQT team as Chief Marketing Officer, bringing with him marketing, creative services and brand management experience from companies such as Puma and WHOOP – the latter recently being valued at $3.6 billion after launching in 2011. Jack’s passion has always been in the health and fitness space, helping to bring new technology to the market to propel these industries forward.

Jack Seitz focused on reaching elite performers and educating professional athletes on the importance of monitoring their vitals for optimal performance while at WHOOP. His work with the company helped to take it from a startup to a household name in a short time. Now, his interest lies in marketing health technology that reaches a much larger market – the everyday consumer.

Jack Seitz was drawn to CONNEQT knowing its products are designed to help monitor daily vital signs and heart metrics as a way to maximize preventative health. With cardiovascular diseases being the world’s leading cause of death globally, Jack felt aligned with CONNEQT’s mission to disrupt the heart health industry by providing devices that measure what matters.

“I’ve had the privilege to work for some of the most innovative companies the sports and health tech industries have seen, and during that time I recognized the importance data can have in helping prevent injuries,” said Jack Seitz, CMO of CONNEQT. “I want to apply my experience to CONNEQT which is doing amazing work in the heart health space. With the amount of people affected by cardiovascular diseases, both knowingly and unknowingly, it is data that will help individuals monitor where their health lies and what they need to adjust to live a long and strong life.”

Lara Rosenbaum
Lara Rosenbaum, Senior Director of Content Strategy, CONNEQT

Lara Rosenbaum has been appointed as CONNEQT’s Senior Director of Content Strategy and will be leading strategy around branded content to help position CONNEQT as a trusted, go-to health resource.

In addition, she will be working alongside Jack to support the company’s marketing goals and needs. Lara brings with her a plethora of knowledge in health journalism, digital branding, and content marketing, having done similar work for Fitbit, Hims, Women’s Health Magazine and other likeminded companies.

Before starting her career, Lara was a member of the U.S. Freestyle Ski Team, which is where her passion for health, fitness and peak performance truly stems from. She was drawn to CONNEQT knowing what its technology is designed to do: helping users learn and understand their health on a deeper level.

As a former athlete herself, Lara understands the importance of knowing how your body operates, and she believes bringing devices to consumers that can provide advanced metrics on their vitals and vascular health is truly game changing.

“As a creative thinker, I’m excited to be joining this incredible team at CONNEQT to help share its goals and vision with the world,” said Lara Rosenbaum, Senior Director of Content Strategy at CONNEQT. “The products in development are remarkable and capable of making a true difference. I’m hopeful to use my experience in the health and fitness industries to showcase just how revolutionary technology like this is, and the power it can have when brought directly to consumers to use as part of their daily routines.”

Lara and Jack both joined CONNEQT after seeing the potential the brand has to normalize heart health tracking so everyday consumers can improve their health and experience true vitality. The two executives are joining the team to work alongside CardieX’s group CEO and Co-founder of CONNEQT, Craig Cooper, who inspired them both to be part of this journey.

These new hires come at a time when CONNEQT is developing its first products, which will begin launching later this year. The first to market will be the CONNEQT “Pulse” – a dual blood pressure monitor anticipated to be the first consumer vital signs monitor to measure central blood pressure using CardieX’s patented SphygmoCor® technology. Additionally, CONNEQT will be branching shortly thereafter into the health wearable space with the CONNEQT Band, which will include a full suite of patented health parameters as well as unique health and wellness features focused on heart health.

“Jack and Lara bring with them not only a great deal of industry leading experience, but also an abundance of passion for CONNEQT and what we are doing in the heart health space,” said Craig Cooper, Group CEO and Co-founder of CONNEQT. “It is a great honor to be able to bring their expertise to our company, and I look forward to seeing what they accomplish.”

SourceCONNEQT

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”